Published date: Mar 15 2021

Journal Title: KnE Life Sciences

Issue title: The 4th International Virtual Conference on Nursing

Pages: 979-990

DOI: 10.18502/kls.v6i1.8774

Novie Elvinawaty Maulikunoviemauliku.unjani@gmail.comPublic Health Study Program, Sekolah Tinggi Ilmu Kesehatan Jenderal Achmad Yani, Cimahi, Indonesia

Multidrug-resistant tuberculosis (MDR-TB) is a tuberculosis infection that is resistant to the treatment at least two of the most powerful anti-tuberculosis drugs, such as Isoniazid and Rifampisin. Increased cases of MDR-TB in morbidity and mortality become obstacles in the control of tuberculosis (TB), thus requiring supportive treatment of natural ingredients that can contribute in the treatment of TB, such a noni fruit. The main objective of this study was extract of noni fruits to inhibition the growth of strain MDR-TB bacteria, and compered it with the anti-TB drugs. The Morinda c. Linn (Noni) fruits was extraced by ethanol (96%). The extract was filtered through whatman No.1 filter paper, evaporated to dryness on a water bath until the solvent evaporated completely and yield of the crude extract. The experiment were divided into 3 groups, i.e.: negative control: group I; positive control: group II; crude extracts noni fruit: group III: combinations of crude extracts noni fruit and anti-TB drugs (K, AK, and OF). Each group was divided into three groups’ doses of 30 mg/ml, 40 mg/ml and 50 mg/ml. The Anti-tuberculosis activities of extracts noni fruit and K, AK, and OF against TB-MDR bacteria were tested by susceptibility test using proportion method in Lowenstein-Jensen (LJ) media.The anti-tubercular activity of noni fruits was determined by the minimum inhibitory concentration (MIC) of the bacterial growth at various doses 30 mg/ml, 40 mg/ml, and 50 mg/ml. The research design used post-test only contol group, and analyzed using analysis of variance and post hoct test. The extracted of Morinda c.Linn (noni) fruits have antitubercular activity to inhibiton of growth MDR-TB bacteria at various doses (p value=0,000). At a dose 30 mg/mlthe mean rate of the growth colonies of MDR TB-bacteria whit the mean rate 59,00 ± 27,81, and at a dose 40 mg/ml was1,50 ± 2,81. While at a dose of 50 mg/ml the bacterial colonies of MDR-TB did not grow in media. The combination of Morinda c.Linn (noni) fruit with anti-tuberculosis drugs, was the smallest groups to inhibit and eliminate MDR-TB bacteria at a dose 30 mg/ml(0,00 ± 00.00). The experimental results confirmed the extracted of Morinda c.Linn (noni) fruits have antitubercular activity as well as anti-TB drugs, and the combination of the extracted of Morinda c.Linn (noni) fruits and anti-TB drugs was the best groups to inhibiton of growth MDR-TB bacteria.

Keywords: TB-MDR Bacteria, Morinda c. Linn (Noni), Anti-TB drugs, Anti-tubercular activity, MIC.

[1] WHO. (2016). Global Tuberculosis Report. Switzerland.


[2] WHO. (2016). Multidrug-Resistant Tuberculosis Fact Sheet 2016, 2015–2016. Switzerland.


[3] Palomino, J. and Martin, A. (2014). Drug Resistance Mechanisms in Mycobacterium Tuberculosis. Antibiotics, vol. 3, issue 3, pp. 317–340.


[4] WHO. (2016). WHO Treatment Guidelines for Drug-Resistant Tuberculosis. Geneva: World Health Organisation.


[5] Region, S. A. (2015). Tuberculosis Control in South-East Asia Region.


[6] WHO. (2016). Tuberculosis Profile. Pan American Health.


[7] Singh, R. (2012). Morinda Citrifolia L. (Noni): A Review of the Scientific Validation for its Nutritional and Therapeutic Properties. Journal of Diabetes and Endocrinology, vol. 3, issue 6, pp. 77–91.


[8] Wang, M.-Y., et al. (2002). Literature Review and Recent Advances in Noni Research. Acta Pharmacol Sin, vol. 23, issue 12, pp. 1127–1141.


[9] Solomon, N. (1999). The Noni Phenomenon, Discover the Powerful Tropical Healer that Fights Cancer. Losers Hight Blood Preasure and Relives Chronic Plan. South Geneva Rood: Direct Source Publising.


[10] West, B. J., et al. (2006). A Safety Review of Noni Fruit Juice. Journal of Food Science, vol. 71, issue 8, pp. 100–106.


[11] Gupta, R. K. and Patel, A. K. (2013). Do The Health Claims Made for Morinda Citrifolia (Noni) Harmonize with Current Scientific Knowledge and Evaluation of its Biological Effects. Asian Pac J Cancer Prev, vol. 14, issue 8, pp. 4495–4499.


[12] Peter, P I. (2007). Clinical Research on Morinda Citrifolia L. Noni Research Cinical Journal, vol.1.


[13] Ali, M., Kenganora, M. and Manjula, S. N. (2016). Health Benefits of Morinda citrifolia (Noni): A Review. Pharmacognosy Journal, vol. 8, issue 4, pp. 321–334.


[14] Srinivasahan, V. and Durairaj, B. (2015). In Vitro Cytotoxic and Apoptotic Activity of Polysaccharide Rich Morinda Citrofolia Fruit on Mcf-7 Cells. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, issue 2, pp. 190–193.


[15] Haque, M. and Rao, U. S. M. (2013). Modulatory Effect of Mengkudu Fruit on the Activities of Key Enzymes of Glucose Synthesis and Utilization Pathways of Diabetic Induced Rats. Journal of Pharmacy Research, vol. 7, issue 1. DOI: 10.1016/j.jopr.2013.01.003


[16] Pai, A. R., et al. (2015). Green Synthesis and Characterizations of Silver Nanoparticles using Fresh Leaf Extract of Morinda Citrifolia and its Anti-Microbial Activity Studies. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, issue 3. Page 459-461


[17] Malinggas, F., Pangemanan, D.H.C. and Mariati, N W. (2015). Uji Daya Hambat Ekstrak Buah Mengkudu (M. Citrifolia L.) Terhadap Pertumbuhan Streptococcus Mutans Secara In Vitro. Pharmacon Jurnal Ilmiah Farmasi – Unsrat, vol. 4, issue 4, pp. 22–26.


[18] Gupta, R. K. and Patel, A. K. (2013). Do the Health Claims made for Morinda Citrifolia (Noni) Harmonize with Current Scientific Knowledge and Evaluation of its Biological Effects. Asian Pacific Journal of Cancer Prevention. 14(8):4495-4499. DOI: 10.7314/APJCP.2013.14.8.4495


[19] Yang, J., Afaisen, S. J. and Gadi, R. (2016). Antimicrobial Activity of Noni Fruit Essential Oil on Escherichia Coli O157:H7 and Salmonella Enteritidis 1, January issue, pp. 1–10.


[20] Saludes, J. P., et al. (2002). Antitubercular Constituents from the Hexane Fraction of Morinda citrifolia Linn. (Rubiaceae). Phytotherapy Research, vol. 16, issue 7, pp. 683–685.


[21] Mauliku, N. E., et al. (2017). Anti-Tubercular Activity of Extract and Coumponds of Noni (Morinda citrifolia Linn). International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, issue 12, pp. 105–109.


[22] Paiva, P. M. G., et al. (2010). Antimicrobial Activity of Secondary Metabolites and Lectins From Plants. Current Research, Tecnology and Education Topics in Applied Microbiology and Microbial Biotechnology, pp. 396–406.


[23] Markandeyan, D., et al. (2015). Virtual Screening of Phytochemicals of Morinda Citrifolia as AntiInflammatory and Anti-Alzheimer Agents using Molegro Virtual Docker on P38α Mitogen-Activated Protein Kinase Enzyme. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, issue 6, pp. 141–145.


[24] Deng, S., West, B. J. and Jensen, C. J. (2010). A Quantitative Comparison of Phytochemical Components in Global Noni Fruits and their Commercial Products. Food Chemistry, vol. 122, issue 1, pp. 267–270.


[25] Lv, L., et al. (2011). Chemical Components of the Roots of Noni (Morinda Citrifolia) and their Cytotoxic Effects. Fitoterapia, vol. 82, issue 4, pp. 704–708.


[26] Motshakeri, M. and Ghazali, H. M. (2015). Nutritional, Phytochemical and Commercial Quality of Noni Fruit: A Multi-Beneficial Gift from Nature. Trends in Food Science and Technology, vol. 45, issue 1, pp. 118–129.


[27] Sathishkumar, G., et al. (2012). Phyto-Synthesis of Silver Nanoscale Particles using Morinda Citrifolia L. and its Inhibitory Activity against Human Pathogens. Colloids and Surfaces B: Biointerfaces, vol. 95, March issue, pp. 235–240.


[28] Brooks, G. F. and Carroll, K. C. (2007). Mycobacteria. In M. Jawetz and Adelberg (Eds.), Medical Microbiology (24th ed.). USA: The McGraw-Hill Companies, Inc., pp. 320–331.


[29] Sastroasmoro, S. I. (2014). Dasar-Dasar Metodologi Penelitian Klinis. Jakarta: Sagung Seto.


[30] Ríos, J. L. and Recio, M. C. (2005). Medicinal Plants and Antimicrobial Activity. Journal of Ethnopharmacology.


[31] WHO. (2014). Companion Handbook. Geneva: World Health Organization.


[32] Antara, N. S. and Prabanca, V. G. (2014). Aktivitas Antimikroba Ekstrak Bubuk Buah Mengkudu (Morinda citrifolia L.) Terhadap Pertumbuhan Bakteri Patogen, vol. 1, issue 1, pp. 1–9.


[33] West, Brett J., et al. (2012). Antimicrobial Activity of an Iridoid Rich Extract from Morinda citrifolia Fruit. Current Research Journal of Biological Science, vol. 4, issue 1, pp. 52–54.


[34] Dewi, N. (2012). Khasiat dan Cara Olah Mengkudu Untuk Mengobati Berbagai Penyakit. Yogyakarta: Pustaka Baru Press.


[35] Potterat, O. and Hamburger, M. (2007). Morinda Citrifolia (Noni) fruit - Phytochemistry, Pharmacology, Safety. Planta Medica, vol. 73, issue 3, pp. 191–199.


[36] George, S. A., et al. (2017). Comprehensive in Vitro Evaluation of Pharmacological Activities of Selected Plant Extracts and Gas Chromatograph Y-Mass Spectrometry Profiling of Flacourtia Jangomas Flower Extract, Asian Journal of Pharmaceutical and Clinical Research 10(5):237 vol.10, issue 5. DOI: 10.22159/ajpcr.2017.v10i5.17419


[37] Al-Otaibi, J. S. and Gogary, T. M. (2017). Synthesis of Novel Anthraquinones: Molecular Structure, Molecular Chemical Reactivity Descriptors and Interactions with DNA as Antibiotic and Anti-Cancer Drugs. Journal of Molecular Structure, vol. 1130, pp. 799–809.


[38] Arya, V. (2011). A Review on Anti-Tubercular Plants. International Journal of PharmTech Research, vol. 3, issue 2, pp. 872–880.


[39] Martins, D. and Nunez, C. V. (2015). Secondary Metabolites from Rubiaceae Species. Molecules, vol. 20, issue 7, pp. 13422–13495.


[40] Pandy, V., et al. (2014). Effect of Noni (Morinda citrifolia Linn.) Fruit and Its Bioactive Principles Scopoletin and Rutin on Rat Vas Deferens Contractility: An Ex Vivo Study. The Scientific World Journal, pp. 1–11.


[41] Pitaloka, D. A. E. and Sukandar, E. Y. (2017). in Vitro Study of Ursolic Acid Combination FirstLine Antituberculosis Drugs Against Drug-Sensitive and Drug-Resistant Strains of Mycobacterium Tuberculosis. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, issue 4, pp. 8–10.